Detection of Disease in the Upper Tract

An Observational Study of Cxbladder Performance for Detection or Rule-out of Upper Tract Urothelial Cancer

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05349812

Acronym

DEDUCT

Enrollment

Registered

2022-04-27

Start date

2022-11-30

Completion date

2023-12-31

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Tract Urinary Carcinoma

Keywords

observational upper urinary tract carcinoma hematuria

Brief summary

An observational study of Cxbladder performance for detection or rule-out of upper tract urothelial cancer. Subjects will be prospectively recruited to a single arm observational study to validate the performance characteristics of Cxbladder for suspected (UTUC) or for patients with a history of UTUC and are under surveillance for recurrence of disease.

Detailed description

This is a single arm observational study prospectively recruiting eligible subjects with no apparent UC of the bladder following white light cystoscopy who have positive or suspicious urine cytology or imaging results. Participants will undergo all clinical investigations as prescribed by the physician as per standard of care with addition of urine sampling to enable Cxbladder and central urine cytology testing. A mid-stream voided urine sample collected at the time of appointment will be used for Cxbladder and central urine cytology testing. Cxbladder and central cytology results will not be reported to the physician. Urine sample testing will occur at Pacific Edge Ltd laboratories (Dunedin, New Zealand). Central urine cytology will be processed by an independent testing laboratory (Southern Community Laboratories, Dunedin, New Zealand). The remainder of the urine sample will be used for dipstick analysis of Specific Gravity, Leucocytes, Nitrites, Blood, Haemoglobin, and pH. The unused portion of this sample will be used for local cytology and any other analysis as deemed clinically appropriate. Central urine cytology results are not available to physicians.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

1. Suspected to have UTUC following negative cystoscopy but positive or suspicious imaging and/or urine cytology. 2. Under surveillance for UTUC following a previous confirmed diagnosis of UTUC 3. Able to provide a voided urine sample of the required 30 ml minimum volume 4. Able to give written consent 5. Able and willing to comply with study requirement 6. Aged 18 years or older

Exclusion criteria

1. Prior genitourinary manipulation (flexible or rigid cystoscopy / catheterisation, urethral dilation) in the 14 days before urine collection 2. Total cystectomy of the bladder with bowel urinary diversion 3. Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Performance of Cxbladder for the detection of Upper Tract Urothelial Carcinoma (UTUC)	Up to 36 months	The number of subjects identified with UTUC by Cxbladder testing as verified by the gold standard for clinical diagnosis.

Outcome results